论文部分内容阅读
目的比较吉非替尼和厄洛替尼治疗非小细胞肺癌(NSCLC)的疗效和安全性。方法回顾性分析中山大学附属第五医院44例患者的临床资料,均口服吉非替尼250 mg,1次/d或厄洛替尼150 mg,1次/d,直至病情进展,比较两组的疗效,无进展生存时间及不良反应。结果吉非替尼和厄洛替尼两组患者的有效率分别为29.2%和25%(P=0.757),疾病控制率为83.3%和75%(P=0.162),无进展生存时间为7.6个月和6.2个月(P=0.995),两组差异均无统计学意义。不良反应如腹泻、皮疹等发生也相似。结论吉非替尼和厄洛替尼治疗晚期NSCLC疗效和安全性相似。
Objective To compare the efficacy and safety of gefitinib and erlotinib in the treatment of non-small cell lung cancer (NSCLC). Methods The clinical data of 44 patients in the Fifth Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. Both of them were given gefitinib 250 mg once daily or erlotinib 150 mg once daily until the progression of the disease. The efficacy, progression-free survival time and adverse reactions. Results The effective rates of gefitinib and erlotinib were 29.2% and 25% (P = 0.757), disease control rates were 83.3% and 75% (P = 0.162), and the progression-free survival time was 7.6 Months and 6.2 months (P = 0.995), no significant difference between the two groups. Adverse reactions such as diarrhea, rashes and other occurrences are similar. Conclusion The efficacy and safety of gefitinib and erlotinib in the treatment of advanced NSCLC are similar.